Nexstim Plc · OMXHEX:NXTMH
Nexstim — Investor Presentation (September 2018)
24 slides from Nexstim's investor presentation, Sep 25, 2018
Slide 1: Nexstim Plc Corporate Presentation
Nexstim. World leader in personalised, navigated, non-invasive brain stimulation therapy and diagnosis. Martin Jamieson| CEO & Chairman of the Board | Nexstim Plc Mikko Karvinen| CFO | Nexstim Plc Nexstim Plc Corporate Presentation, September 2018
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim – advanced transcranial magnetic stimulation
Nexstim – advanced transcranial magnetic stimulation Unique and Proprietary ▪ Commercial-stage med tech company with a unique, proprietary navigated neuro- Technology stimulation technology for diagnostic and therapeutic applications World Leading Centers Rely ▪ Diagnostic application well establish
Slide 4: Nexstim's TMS system differentiated by E-Field Navigation
Nexstim’s TMS system differentiated by E-Field Navigation Leading transcranial magnetic stimulation technology User Interface of Nexstim TMS system • Nexstim’s device facilitates highly accurate pre-surgical mapping • Unique e-field induced modelling • 3D MRI visualisation and stereotactic navigatio
Slide 5: Unique navigated TMS system for diagnostic and therapeutic applications
Unique navigated TMS system for diagnostic and therapeutic applications Use Application Europe US Commercial Status Diagnostic – Installed base of over Navigated Brain Pre-surgical mapping CE marked FDA approved 150 systems Stimulation (NBS) Multiple systems Therapeutic – Depression CE marked FDA ap
Slide 6: Navigated Brain Stimulation
Navigated Brain Stimulation Proprietary technology enabling substantial patient benefit in brain cancer surgery, commercially validated
Slide 7: Nexstim's NBS is the only available pre-surgical mapping technology
Nexstim’s NBS is the only available pre-surgical mapping technology World-leading Centers Rely on Nexstim‘s Pre-surgical NBS Significantly Improves Clinical Outcomes Mapping Technology NBS Selected institutions out of the 150 ones currently NBS helps surgeons to prepare better and to be more aggress
Slide 8: Navigated Brain Therapy®
Navigated Brain Therapy® Smart, focused and drug-free
Slide 9: NBT® - personalised method of treatment
NBT® - personalised method of treatment Process: • Map the motor cortex: Magnetic Stimulation ➢e-field modeling ensures navigation accuracy Max e-field ➢The point of Max stimulation stimulation response is measured through response EMG (hot spot) ➢Establish motor threshold (MT) DLPFC at hot spot Dor
Slide 10: Nexstim E-field navigation vs. line navigation
Nexstim E-field navigation vs. line navigation TMS coil TMS coil • Line navigation is E-field E-field inaccurate as it doesn’t maximum Line navigation maximum account for the distortion point caused by bone and brain matter • Nexstim’s E-field navigation accounts for that distortion • Non-navigated
Slide 11: Navigated Brain Therapy® in Depression
Navigated Brain Therapy® in Depression Entering a rapidly growing market with a differentiated product
Slide 12: NBT® for Depression
NBT® for Depression Nexstim depression business opportunity Market size of estimate2 People affected by MDD globally 216m • Major depressive disorder affects 2-5% of the Patients not responding to medicines population in developed countries1 39m and seeking treatment • Existing psychotherapy and pha
Slide 13: Existing reimbursement for depression treatment and private pay represent compelling opportunity in the US
Existing reimbursement for depression treatment and private pay represent compelling opportunity in the US Economic Benefit to US TMS Centre or Psychiatric Clinic Commercialisation approach (Pay-per-use lease)1 • Most major commercial payers now reimburse TMS treatment for depression in the US and 1
Slide 14: NBT® geographic focus for depression in the US
NBT® geographic focus for depression in the US Build a direct sales field organization NORTHEAST STATES2 comprised of sales, clinical support and Population: 67 Million operations distributed across existing US Practices using TMS: 196 NBS geography and recruit sophisticated TMS Groups: 47 and well
Slide 15: Commercialization and Go-To Market Approach – Europe & Asia
Nexstim Brain Therapy - Commercialization and Go- To Market Approach – Europe & Asia Actions on established markets • Strong distributor organization • Cross-selling NBS with NBT® • Five university hospitals in Finland using a Nexstim system for both depression and pain treatments • Patient registry
Slide 16: Development Actions for NBT® for Depression
Development Actions for NBT® for Depression • Technology • Automatic identification of the DLPFC to increase effectiveness of the therapy treatment process • Advanced user interface for NBT® system • System cost reduction programme • Wireless EMG • Business Development • Patient treatment registry •
Slide 17: Nexstim Brain Therapy – Building the commercial organization
Nexstim Brain Therapy – Building the commercial organization ▪ Direct sales team for the US and a mix of both direct and distributor partnerships for other geographies ▪ Depression advisory panel established. Leverage strong neurosurgical KOL network ▪ The current US commercial organization of eight
Slide 18: Navigated Brain Therapy® in Neuropathic Pain
Navigated Brain Therapy® in Neuropathic Pain
Slide 19: NBT® for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Nexstim neuropathic pain business opportunity Market size of estimate2 People affected by chronic • There are about 10 million addressable neuropathic pain 285m neuropathic pain annually patients in the US and Europe1 Patients not responding to medicines and seeking
Slide 20: Business summary
Business summary 1 Only TMS system to provide accurate, personalised targeting of key areas of treatment Commercially validated in pre-surgical mapping with systems installed in more than 150 2 hospitals 3 First installations for depression in multiple sites across three continents 4 Focused strateg
Slide 21: Thank you!
Nexstim Thank you!
Slide 22: The Board of Directors
Appendix The Board of Directors Name Education Relevant experience Nationality Currently board member of C-Major Ltd, LightPoint Martin Jamieson, University of the Arts (CDT) London Medical Ltd and Schuco Ltd. Martin was a NED at 2015 Chairman Higher National Diploma - Business Studies Medway NHS Ho
Slide 23: Management team
Appendix Management team Name Current position (Nexstim Education Relevant experience Nationality since) Currently board member of C-Major Ltd, LightPoint Medical Ltd and Schuco Ltd. University of the Arts (CDT) London Martin Jamieson CEO & Chairman of the Board Martin was a NED at Medway NHS Higher
Slide 24: Key Performance Indicators
Appendix Key Performance Indicators EUR in thousands H1 2018 H1 2017 FY 2017 NBS system, net 6 months 6 months 12 months sales grew by 2% Net sales 1,079.3 1,058.4 2,645.3 Includes EUR - Personnel expenses -1,523.8 -1,475.3 -3,334.7 1,733 thousand of financial expenses Depreciation and amortisation